# Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

> **NCT07389265** · PHASE3 · RECRUITING · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 480 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** Erbitux (Cetuximab)
- **DRUG:** Bevacizumab
- **DRUG:** FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
- **DRUG:** FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

## Key facts

- **NCT ID:** NCT07389265
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2030-10
- **Final completion:** 2030-10
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389265, "Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07389265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*